The Federal Trade Commission on Tuesday offered the biopharma industry a peek into how it may try to crack down on M&A. As part of generic drug company Hikma’s proposed $375 million acquisition of generic injectable producer Custopharm, the commission is requiring that Hikma not acquire a generic corticosteroid drug known as triamcinolone acetonide, or TCA, and that Custopharm’s parent company retain and transfer the drug to a subsidiary, Long Grove Pharmaceuticals.
For $375 million upfront and another $50 million in milestone payments, Hikma is buying U.S. generic injectable player Custopharm, the U.K. company unveiled Monday.
Enforcement Report - Week of September 1, 2021
Custopharm`s Generic Calcitonin salmon Receives Approval in US